Gcsf Injection in Women With Repeated Implantaiton Failure
Effects of Exogenous Recombinant GCSF in Patients With Repeated Implantation Failure - A Randomized Single-blind Trial
Sponsor: Clinique Ovo
Terminated
Recruitment difficulty
Listed as NCT02149277, this PHASE3 trial focuses on Repeated Embryo Implantation Failure and remains terminated or withdrawn. Sponsored by Clinique Ovo, it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
-
Oct 2021 — May 2022 [monthly]
Suspended PHASE3
-
Mar 2021 — Oct 2021 [monthly]
Suspended PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Suspended PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Suspended PHASE3
-
Sep 2019 — Oct 2020 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
-
Aug 2018 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinique Ovo
For direct contact, visit the study record on ClinicalTrials.gov .